Evidence map›Paper›PMID 32189935›Full record

ArticleJournal of clinical and experimental hepatology

Successful Treatment of Disseminated Hepatocellular Carcinoma After Liver Transplantation With Nivolumab.

Waseem Amjad, Sandy Kotiah, Ankur Gupta, Michael Morris, Li Liu, Paul J Thuluvath

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical and experimental hepatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 4 pooled it
2.4field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 4 syntheses or guidelines pooled it, 47 citations in OpenAlex.

  1. Guideline
  2. Immune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysis.Liver international : official journal of the International Association for the Study of the Liver · 2023
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Waseem AmjadInstitute of Digestive Health & Liver Disease, Mercy, Medical Center, Baltimore MD 21202, USA.
Sandy KotiahDepartments of Oncology, Mercy, Medical Center, Baltimore MD 21202, USA.
Ankur GuptaRadiology and Nuclear Medicine, Mercy, Medical Center, Baltimore MD 21202, USA.
Michael MorrisRadiology and Nuclear Medicine, Mercy, Medical Center, Baltimore MD 21202, USA.
Li LiuPathology, Mercy, Medical Center, Baltimore MD 21202, USA.
Paul J ThuluvathInstitute of Digestive Health & Liver Disease, Mercy, Medical Center, Baltimore MD 21202, USA.
Mercy Medical Center · USMercy Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The use of immunotherapy in transplant recipients is considered a contraindication because of very high risks for graft loss. The graft loss is to be expected because cytotoxic T-lymphocyte-associated protein-4 and programmed death 1 pathways are implicated in graft tolerance. In this case report, we describe a woman with recurrent, disseminated hepatocellular carcinoma who was successfully treated with nivolumab, an immune checkpoint inhibitor.

Indexed as

CPI, immune checkpoint inhibitorHCC, Hepatocellular carcinomaimmune checkpoint inhibitorPD-1, programmed death -1PD- L1, programmed death -ligand 1post liver transplantrecurrent HCC

Identifiers

PMID32189935
PMCPMC7067990
OpenAlexW2993563129

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.